The withdrawn products, Rhinatiol, Bronkirex and Carbocistene, were pulled after a patient detected an “unusual odour.”
While Sanofi has yet to issue a statement on the recall, a Retuers report suggested that phenol levels were “well below a dangerous level,” and that the move was a precautionary measure.
While relatively small scale, the recall comes at a busy time for Sanofi, which is trying to both restructure its R&D operations and defend the safety of its diabetes drug Lantus.